FDA warned Lupin's Novel Laboratories over manufacturing violations including equipment cross-contamination and unvalidated temazepam capsules.
What happened
FDA inspected the Somerset, New Jersey facility from September 10 to November 5, 2020. Investigators found active drug residue on a tablet press and air duct that had been documented as clean, and found temazepam 15 mg and 30 mg capsules made with unvalidated process and equipment changes, with out-of-specification content uniformity results. FDA also cited inadequate quality-unit oversight and incomplete annual product reviews.
What FDA found
The company failed to establish and follow adequate written procedures for cleaning and maintenance of equipment; FDA found active drug residue on a tablet press and air duct documented as clean.
21 CFR 211.67(b)The company failed to establish adequate written procedures for production and process control; temazepam capsule manufacturing was transferred with unvalidated process and equipment changes and had out-of-specification content uniformity results.
21 CFR 211.100(a)The quality unit did not adequately oversee cleaning validation limits or complete annual product reviews as required.
21 CFR 211.22(d); 21 CFR 211.180(e)
What FDA wants
Provide a written response within 15 working days describing corrections, including testing reserve samples for cross-contamination, a retrospective cleaning assessment, corrective action plans, validation improvements, and quality-unit remediation. If corrective actions cannot be completed in 15 working days, state the reasons and schedule.
Who should pay attention
- brands and distributors that buy finished drug products from Lupin or Novel Laboratories
- patients taking temazepam capsules or other products made on shared equipment
- quality teams managing shared equipment cleaning and process validation
This is a summary. Read the original letter on fda.gov.